Serum Pepsinogen as a Predictor for Gastric Cancer Death

Chiang, Tung‐Liang; Chiu, Sherry Yueh Hsia; Chen, Sam Li Sheng; Yen, Amy Ming Fang; Fann, Jean Ching Yuan; Liu, Cheng Ying; Chou, Chia-Hung; Chiu, Han–Mo; Shun, Chia‐Tung; Wu, Ming Shiang; Lin, Jaw Town; Lee, Yi–Chia; Chen, Chien-Jen; Lin, Ming

doi:10.1097/mcg.0000000000000992

Cited by 22 publications

(18 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In CAG patients, we also noticed that our PGI level and PG I/PG II ratios are slightly higher when compared with other reports[ 9 - 12 ], and as all the CAG patients have histological confirmation, we therefore consider this effect could be due to patient population- or region-based variations, or might be due to variations from the degrees of atrophy itself. Future studies are required to explain these discrepancies.…”

Section: Discussionsupporting

confidence: 62%

“…Application of G-17, PG I, PG II levels and PG I/PG II ratios in gastric cancer epidemiology study have been reported extensively, although their predicative values in stepwise gastric disease in clinical studies have not been very well defined. Previous investigations have generated inconsistent conclusions[ 9 - 12 ], and our results using AUROC analysis (Figure 2 ) indicated relatively low predictive value range from 0.529-0.786 for PU, CAG and GC patients, and type I H. pylori infection is the major factor that affects their levels as the disease progresses. These data provide insight to evaluate their application during clinical practice and are helpful in explaining the results.…”

Section: Discussioncontrasting

confidence: 49%

“…Gastric inflammation can lead to increased release of both pepsinogens into the bloodstream, with a greater increase in PG II than in PG I[ 20 ]. Other previous studies[ 8 , 9 , 21 ] have reported that low PG I levels and/or low PG I/PG II ratios are associated with increased risk of gastric cancer. PG I < 70 µg/L and PG I/PG II ratio < 3.0 have been frequently applied as the thresholds for defining population with high-risk of gastric cancer.…”

Section: Discussionmentioning

confidence: 91%

“…Serological detection of pepsinogen (PG) I, II, PG I/PG II ratio and gastrin-17 (G-17) provide valuable information on the status of gastric mucosa, and they have been used as epidemiological markers for gastric cancer risk investigation[ 9 - 12 ]. Studies have indicated that low concentrations of PG I and PG I/PG II ratios are indicators of gastric atrophy, which are linked with elevated gastric cancer risk[ 9 , 10 ]. However, others have indicated that the results are not consistent and not sensitive enough to replace endoscopy[ 11 , 12 ].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Type I and type II Helicobacter pylori infection status and their impact on gastrin and pepsinogen level in a gastric cancer prevalent area

Yuan

Zhao

Zhou

et al. 2020

WJG

View full text Add to dashboard Cite

BACKGROUND Type I Helicobacter pylori ( H. pylori ) infection causes severe gastric inflammation and is a predisposing factor for gastric carcinogenesis. However, its infection status in stepwise gastric disease progression in this gastric cancer prevalent area has not been evaluated; it is also not known its impact on commonly used epidemiological gastric cancer risk markers such as gastrin-17 (G-17) and pepsinogens (PGs) during clinical practice. AIM To explore the prevalence of type I and type II H. pylori infection status and their impact on G-17 and PG levels in clinical practice. METHODS Thirty-five hundred and seventy-two hospital admitted patients with upper gastrointestinal symptoms were examined, and 523 patients were enrolled in this study. H. pylori infection was confirmed by both 13 C-urea breath test and serological assay. Patients were divided into non-atrophic gastritis (NAG), non-atrophic gastritis with erosion (NAGE), chronic atrophic gastritis (CAG), peptic ulcers (PU) and gastric cancer (GC) groups. Their serological G-17, PG I and PG II values and PG I/PG II ratio were also measured. RESULTS A total H. pylori infection rate of 3572 examined patients was 75.9%, the infection rate of 523 enrolled patients was 76.9%, among which type I H. pylori infection accounted for 72.4% (291/402) and type II was 27.6%; 88.4% of GC patients were H. pylori positive, and 84.2% of them were type I infection, only 11.6% of GC patients were H. pylori negative. Infection rates of type I H. pylori in NAG, NAGE, CAG, PU and GC groups were 67.9%, 62.7%, 79.7%, 77.6% and 84.2%, respectively. H. pylori infection resulted in significantly higher G-17 and PG II values and decreased PG I/PG II ratio. Both types of H. pylori induced higher G-17 level, but type I strain infection resulted in an increased PG II level and decreased PG I/PG II ratio in NAG, NAGE and CAG groups over uninfected controls. Overall PG I levels showed no difference among all disease groups and in the presence or absence of H. pylori; in stratified analysis, its level was increased in GC and PU patients in H. pylori and type I H. pylori- positive groups. CONCLUSION Type I H. pylori infection is the major form of infection in this geographic region, and a very low percentage (11.6%) of GC patients are not infected by H. pylori . Both types of H. pylori induce an increase in G-17 level, while type I H. pylori is the ma...

show abstract

Section: Discussionsupporting

confidence: 62%

Section: Discussioncontrasting

confidence: 49%

Section: Discussionmentioning

confidence: 91%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Type I and type II Helicobacter pylori infection status and their impact on gastrin and pepsinogen level in a gastric cancer prevalent area

Yuan

Zhao

Zhou

et al. 2020

WJG

View full text Add to dashboard Cite

show abstract

“…Owing to the high risk of gastric cancer in this population, an initial screening programme was implemented in 1995-1998 based on pepsinogen measurements. 20 Mass screening and eradication of H. pylori were launched in 2004, the short-term benefits were evaluated in 2008, and the programme has been fully implemented on a biennial basis since 2012. Repeated screening was done to deal with the dynamic nature of this cohort and the observed increase in eligible subjects.…”

Section: Study Population and Preventive Programmementioning

confidence: 99%

Mass eradication ofHelicobacter pylorito reduce gastric cancer incidence and mortality: a long-term cohort study on Matsu Islands

Chiang

Chang

Chen

et al. 2020

Gut

Self Cite

136

110

View full text Add to dashboard Cite

ObjectiveAlthough mass eradication of Helicobacter pylori has been proposed as a means to eliminate gastric cancer, its long-term effects remain unclear.DesignMass eradication of H. pylori infection was launched in 2004 and continued until 2018 for a high-risk Taiwanese population aged 30 years or older dwelling on Matsu Islands with prevalent H. pylori infection. Test positives for the 13C-urea breath test underwent eradication therapy. We evaluated the effectiveness of the mass eradication in reducing two main outcomes, incidence and mortality rates of gastric cancer, until the end of 2016 and 2018, respectively.ResultsAfter six rounds of mass screening and eradication, the coverage rate reached 85.5% (6512/7616). The referral rate for treatment was 93.5% (4286/4584). The prevalence rates of H. pylori fell from 64.2% to 15.0% with reinfection rates of less than 1% per person-year. The presence and severity of atrophic gastritis and intestinal metaplasia also decreased with time. Compared with the historical control period from 1995 to 2003, the effectiveness in reducing gastric cancer incidence and mortality during the chemoprevention period was 53% (95% CI 30% to 69%, p<0.001) and 25% (95% CI −14% to 51%, p=0.18), respectively. No significant changes were noted in the incidence rates of other digestive tract cancers or the antibiotic resistance rate of H. pylori.ConclusionPopulation-based eradication of H. pylori has significantly reduced gastric cancer incidence with no increase in the likelihood of adverse consequences. A significant reduction in mortality is likely to be achieved with a longer follow-up period.Trial registration numberNCT00155389

show abstract

Helicobacter pylori infection in Africa: comprehensive insight into its pathogenesis, management, and future perspectives

Emmanuel,

Peter,

Peter

et al. 2024

J.Umm Al-Qura Univ. Appll. Sci.

View full text Add to dashboard Cite

Helicobacter pylori is a widespread bacterium that has effectively colonized half of the global population, with Africa having over 70% of the total burden of H. pylori infections (HPI). Considering its acknowledged classification of as bacterial carcinogens and their significant contribution to the development of gastrointestinal disorders such as gastritis, peptic ulcers, and gastric neoplasia, together with their growing resistance to antibiotics. Gaining insight into the etiology of this organism is crucial in order to investigate and develop appropriate treatment strategies. Furthermore, the rise of bacteria that are resistant to antibiotics presents an extra danger in managing this detrimental bacterium. Our review focuses on investigating the presence of H. pylori in Africa and analyzing the various factors that contribute to its extensive prevalence. We simplified the complex mechanisms that H. pylori utilizes to flourish in the human body, with a specific emphasis on its virulence factors and antibiotic resistance. These variables pose significant challenges to conventional treatment strategies. In addition, we analyze both conventional and developing diagnostic methods, as well as the current treatment approaches implemented in various African nations. In addition, we tackle the distinct healthcare obstacles of the region and put-up practical remedies. The main goal of this review is to improve the formulation of more efficient methods for the management and treatment of HPI in Africa.

show abstract

Serum Pepsinogen as a Predictor for Gastric Cancer Death

Abstract: This long-term cohort study shows the usefulness of PG measurement as a biomarker that is specific to the risk of gastric cancer death.

Cited by 22 publications

References 28 publications

Type I and type II Helicobacter pylori infection status and their impact on gastrin and pepsinogen level in a gastric cancer prevalent area

Type I and type II Helicobacter pylori infection status and their impact on gastrin and pepsinogen level in a gastric cancer prevalent area

Mass eradication ofHelicobacter pylorito reduce gastric cancer incidence and mortality: a long-term cohort study on Matsu Islands

Helicobacter pylori infection in Africa: comprehensive insight into its pathogenesis, management, and future perspectives

Contact Info

Product

Resources

About